Clinical Trial Update: Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012) [Phase 3]

View source ↗

Summary

A Phase 3 trial (LEAP-012) evaluating lenvatinib plus pembrolizumab with transarterial chemoembolization in patients with incurable/non-metastatic hepatocellula…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LENVIMA (lenvatinib)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Carcinoma, Hepatocellular | Phase 3 | Status: COMPLETED